Provided by Tiger Fintech (Singapore) Pte. Ltd.

Coherus BioSciences

0.7431
+0.01051.43%
Post-market: 0.7400-0.0031-0.42%17:59 EDT
Volume:1.78M
Turnover:1.33M
Market Cap:86.15M
PE:-0.65
High:0.7705
Open:0.7400
Low:0.7306
Close:0.7326
Loading ...

Coherus BioSciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Apr

Coherus BioSciences Is Maintained at Neutral by UBS

Dow Jones
·
25 Apr

BRIEF-Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio

Reuters
·
14 Apr

Coherus Completes Strategic Transformation With Successful Divestiture of Udenyca® Franchise

THOMSON REUTERS
·
14 Apr

Coherus BioSciences to Repurchase $170 Million Convertible Notes

MT Newswires Live
·
01 Apr

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

THOMSON REUTERS
·
01 Apr

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

GlobeNewswire
·
01 Apr

Coherus BioSciences Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
14 Mar

Coherus BioSciences’ Earnings Call: Growth and Challenges

TIPRANKS
·
12 Mar

Q4 2024 Coherus BioSciences Inc Earnings Call

Thomson Reuters StreetEvents
·
12 Mar

Coherus BioSciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Mar

Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
11 Mar

Coherus BioSciences Reports 2024 Financial Growth

TIPRANKS
·
11 Mar

Coherus BioSciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Mar

Coherus BioSciences Q4 Net Loss Narrows, Revenue Declines

MT Newswires Live
·
11 Mar

Coherus BioSciences: Q4 Earnings Snapshot

Associated Press Finance
·
11 Mar

Coherus BioSciences Q4 2024 Adj. EPS $(0.28) Misses $(0.13) Estimate, Sales $54.144M Beat $47.270M Estimate

Benzinga
·
11 Mar

BRIEF-Coherus BioSciences Q4 Net Income USD -50.696 Million

Reuters
·
11 Mar

Coherus BioSciences Inc - Post Divestiture Cash Expected at $250 Million, Headcount Reduced by 30%

THOMSON REUTERS
·
11 Mar

Coherus BioSciences Inc -Approximately 50 Employees Associated With Udenyca Are Expected to Transfer to Accord Biopharma

THOMSON REUTERS
·
11 Mar